MarketPulse

material misrepresentation

12 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Boston Scientific Faces Securities Lawsuit Over False Electrophysiology Claims

Rosen Law Firm files securities class action against Boston Scientific, alleging false statements about U.S. Electrophysiology segment sustainability. Investors have until May 4 deadline to join.
CWHBSXADMAsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Franklin BSP Realty Trust Faces Securities Class Action Over Dividend Claims

Rosen Law Firm seeks lead plaintiffs with $100K+ losses in $FBRT securities class action alleging false dividend sustainability claims. April 27, 2026 deadline applies.
FBRTFBRTpEDRVNBCSinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Coty Faces Class Action Lawsuit Over Alleged Misstatements on Growth and Profitability

Class action lawsuit filed against Coty Inc. alleging executives made false statements about growth prospects. Investors claim company concealed slowing beauty market growth and margin pressures.
COTYsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Gross Law Firm

Gartner Faces Securities Lawsuit Over Missed Growth Targets Amid Stock Collapse

Class action lawsuit filed against $IT over alleged misleading growth projections. Stock fell 27.55% and 20.87% after earnings misses. Lead plaintiff deadline May 18, 2026.
ITshareholder lawsuitsecurities class action
BenzingaBenzinga··The Law Offices Of Frank R. Cruz

Coty Hit With Securities Fraud Suit Over Undisclosed Beauty Segment Woes

Coty faces securities fraud lawsuit over alleged failure to disclose Consumer Beauty underperformance, margin compression, and fragrance market slowdown between November 2025 and February 2026.
COTYsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

NuScale Power Faces Securities Fraud Lawsuit Over $495M ENTRA1 Energy Deal

NuScale Power faces securities fraud lawsuit over $495M deal with inexperienced partner ENTRA1 Energy; stock fell 12.4% after disclosure.
SMRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Apollo Global Faces Class Action Over Undisclosed Epstein Ties; Stock Tumbles 15%

Robbins LLP filed class action lawsuit against $APO over concealed Jeffrey Epstein communications. Stock dropped from $133.19 to $113.73 following media exposures in February 2026.
APOAPOSAPOpAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

NuScale Power Stock Plummets 12.4% Over $495M ENTRA1 Deal; Securities Fraud Lawsuit Filed

NuScale Power faces securities fraud lawsuit after disclosing $495M payment to inexperienced nuclear startup ENTRA1 Energy, triggering 12.4% stock decline.
SMRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Block & Leviton Llp

Biogen Class Action Certified: Securities Lawsuit Over 2021 Misrepresentation Claims

Federal court certifies class action against Biogen for alleged 2021 securities misrepresentations, affecting purchasers during June-July period.
BIIBclass actionfederal securities laws
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

NuScale's $495M ENTRA1 Deal Sparks Securities Fraud Lawsuit Over Undisclosed Risks

NuScale Power faces class action lawsuit after paying $495M to inexperienced nuclear startup ENTRA1, triggering 12.4% stock plunge and investor claims of material risk concealment.
SMRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Faces Securities Litigation Over Clinical Trial Disclosures

Mereo BioPharma faces securities lawsuit alleging misrepresentations about Phase 3 trial results for setrusumab, causing investor losses.
SNOWMREOsecurities fraudsecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Class Action Lawsuit Filed Against REGENXBIO Over Gene Therapy Safety Disclosures

Law firm sues REGENXBIO for allegedly hiding safety concerns about gene therapy RGX-111. Stock dropped 17.8% after FDA clinical hold due to tumor in trial participant.
RGNXsecurities fraudclass action lawsuit